European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025)
Singapore 05 December 2025 - 07 December 2025
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
20 hours ago
byAudrey Abella
A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.
Tamoxifen interruption for pregnancy feasible in young breast cancer survivors
20 hours ago
Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6
06 Jan 2026
byAudrey Abella
In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).